Form 4 for TARS Tarsus Pharmaceuticals, Inc.
Accepted 2026-03-19 00:00:00 ET · period of report 2026-03-17 · accession 0001827584-26-000009 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-03-19 | 2026-03-17+ | TARS | Neervannan Seshadri | COO | S - Sale | $68.21 | -11.3K | 94.0K | -11% | -$772.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-18 | S | D | 3,610 | $68.71 | 90,369 | D | — | — | |
| 2 | Common | Common Stock | 2026-03-19 | S | D | 4,589 | $67.00 | 85,780 | D | — | — | |
| 3 | Common | Common Stock | 2026-03-17 | S | D | 3,125 | $69.42 | 93,979 | D | — | — |